Sebastian Schneeweiss
Overview
Explore the profile of Sebastian Schneeweiss including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
521
Citations
16884
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kirchgesner J, Wang S, Schneeweiss S
Pharmacoepidemiol Drug Saf
. 2024 Sep;
33(9):e70008.
PMID: 39223963
No abstract available.
12.
Suissa S, Schneeweiss S, Feldman W, Tesfaye H, Wang S
Am J Epidemiol
. 2024 Aug;
PMID: 39191649
Observational studies are increasingly used to provide real-world evidence in regulatory decision-making. The RCT-DUPLICATE initiative conducted observational studies emulating two trials in patients with asthma and three in COPD. For...
13.
DAndrea E, Schneeweiss S, Franklin J, Kim S, Glynn R, Lee S, et al.
Arthritis Rheumatol
. 2024 Aug;
77(1):12-21.
PMID: 39129266
Objective: The objective of this study is to evaluate the concordance of results between the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly (HORIZON)-Pivotal Fracture Trial (PFT) and...
14.
Suissa K, Schneeweiss S, Glynn R, Wexler D, Suissa S, Paik J, et al.
Diabetes Obes Metab
. 2024 Jul;
26(10):4273-4280.
PMID: 39014528
Aim: Non-randomized studies on bariatric surgery have reported large reductions in mortality within 6-12 months after surgery compared with non-surgical patients. It is unclear whether these findings are the result...
15.
Schneeweiss S, Desai R, Ball R
Am J Epidemiol
. 2024 Jul;
194(2):315-321.
PMID: 39013780
Electronic health record (EHR) data are seen as an important source for pharmacoepidemiology studies. In the US health-care system, EHR systems often identify only fragments of patients' health information across...
16.
Papukchieva S, Kim H, Stratil A, Magurne E, Jonckheere A, Kahn M, et al.
Mult Scler Relat Disord
. 2024 Jul;
88:105751.
PMID: 38968925
Background: The hit-hard-and-early (HHAE) strategy where treatment is initiated with high-efficacy therapies opposed to low-efficacy therapies presents a potential paradigm shift in multiple sclerosis (MS) management. This study aimed to...
17.
Schneeweiss S
Clin Pharmacol Ther
. 2024 Jul;
116(5):1168-1173.
PMID: 38952236
Almost all external control arm analyses to contextualize findings of a single arm trial struggle with two key issues: the lack of baseline randomization, and equally important, the difference in...
18.
Health Care Utilization and Costs Associated With Empagliflozin in Older Adults With Type 2 Diabetes
Htoo P, NajafZadeh M, Tesfaye H, Schneeweiss S, Wexler D, Glynn R, et al.
Diabetes Care
. 2024 Jun;
47(11):1900-1907.
PMID: 38917305
Objective: We compared health care resource utilization (HCRU) and costs for inpatient and outpatient services and dispensed medications in older adults with type 2 diabetes initiating empagliflozin versus dipeptidyl peptidase...
19.
Desai R, Bradley M, Lee H, Eworuke E, Weberpals J, Wyss R, et al.
Am J Epidemiol
. 2024 Jun;
193(11):1600-1608.
PMID: 38825336
Unmeasured confounding is often raised as a source of potential bias during the design of nonrandomized studies, but quantifying such concerns is challenging. We developed a simulation-based approach to assess...
20.
Wang S, Lin K, Schneeweiss S
Pharmacoepidemiol Drug Saf
. 2024 May;
33(5):e5813.
PMID: 38720425
Direct oral anticoagulants (DOACs) revolutionized the management of thromboembolic disorders. Clinical care may be further improved as Factor XIs undergo large-scale outcome trials. What role can non-randomized database studies play...